Skylark Bio

News

Skylark Bio has dosed the first patient in a phase 1/2 trial of SKY-GJB2, a gene therapy for the most common form of genetic deafness in children.

Oncology

Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static diagnostics.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.